Ilaria Cutini
A5010791044- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Viral Infectious Diseases and Gene Expression in Insects
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Autoimmune and Inflammatory Disorders Research
- Chemokine receptors and signaling
- Polyomavirus and related diseases
- Immune Cell Function and Interaction
- Cancer Genomics and Diagnostics
- Cytomegalovirus and herpesvirus research
- Sarcoma Diagnosis and Treatment
- Virus-based gene therapy research
- Complement system in diseases
- Renal Diseases and Glomerulopathies
- Parvovirus B19 Infection Studies
- Platelet Disorders and Treatments
- Drug-Induced Ocular Toxicity
- Immune cells in cancer
Azienda Ospedaliero-Universitaria Careggi
2013-2025
University of Florence
2012-2020
Tumour Institute of Tuscany
2012-2016
Ospedali Riuniti di Ancona
2013
Neutropenia may limit the use of valganciclovir treatment for cytomegalovirus (CMV) infection following hematopoietic cell transplant (HCT). A phase 2 study indicated efficacy maribavir with fewer treatment-limiting toxicities than valganciclovir.
Axicabtagene ciloleucel showed efficacy for relapsed/refractory large B-cell lymphomas (LBCL), including primary mediastinal (PMBCL); however, only few PMBCLs were reported. Aim was to evaluate and safety of axicabtagene in patients with PMBCL compared those other LBCL, enrolled the Italian prospective observational CART-SIE study. (n = 70) younger, higher percentage bulky refractory disease, LBCLs 190). Median follow-up time infused 12.17 months (IQR 5.53,22.73). The overall (complete +...
Mutations in CCAAT/enhancer binding protein α (CEBPA) occur 5–10% of cases acute myeloid leukemia. CEBPA-double-mutated usually bear biallelic N- and C-terminal mutations are associated with a favorable clinical outcome. Identification CEBPA mutants is challenging because the variety mutations, intrinsic characteristics gene technical issues. Several screening methods (fragment-length analysis, expression array) have been proposed especially for large-scale use; although efficient, they...
Abstract Background Chimeric antigen receptor T cells (CAR-T) represent an innovation but raise issues for healthcare payers because of the uncertainty on impact at market launch, high cost and important organisational impact. The literature has focused their assessment, appraisal access solutions. No evidence costs sustained to implement CAR-T is available a few studies reported clinical pathway, including activities that are remunerated through inpatient or outpatient...
Pseudoprogression is a complication observed following CAR-T therapy that can mimic disease progression; however, its incidence not well defined. This phenomenon driven by robust inflammatory response due to the recognition of cells targeting lymphoma. Misinterpreting pseudoprogression as true progression could result in unnecessary alterations treatment regimen. Here, we present case 69-year-old patient with diffuse large B-cell lymphoma (DLBCL) who received axicabtagene ciloleucel fourth...
Summary Background In the letermovir-primary-prophylaxis (LET-PP) era epidemiology of human-cytomegalovirus-infections (HCMV-i) in allogeneic hematopoietic-stem-cell-transplant (allo-HSCT) has changed Methods We prospectively evaluated incidence and risk factors for clinically significant (CS) HCMV-i at 180 days from transplant 1-year overall-survival 1,310 allo-HSCTs performed January 2021 to March 2022 according LET-PP use. Results The cumulative CS-HCMV-i 100 were 3.8% 16% patients who...
Clofarabine has been shown to be effective in AML patients, either as single agent or, mainly, association with intermediate dose cytarabine. Based on these reports, we conducted a preliminary study combining clofarabine and cytarabine patients who relapsed or failed respond at least two induction therapies. We treated 47 affected by relapsed/refractory regimen including 22.5 mg/m(2) daily days 1-5, followed after 3 hr 1 g/m(2) 1-5. Ten received further consolidation cycle day 1-4. Among the...
Background. In acute myeloid leukemia (AML), CXCR4 expression has been correlated with leukocytosis and prognosis. Methods. We quantified by flow cytometry on leukemic cells in 142 AML patients. Results. confirm a correlation between high burden. Furthermore, we documented platelet count, dysplastic megakaryopoiesis, hepato-splenomegaly extra-hematological disease. NPM1-mutated displayed significantly higher intensity of compared to NPM1-wt cases: it is conceivable its clinical phenotype be...
Brexucabtagene autoleucel (brexu-cel) has revolutionized the treatment of patients affected by mantle cell lymphomas. In this prospective, observational multicentre study, we evaluated 106 patients, with longitudinal brexu-cel kinetics in peripheral blood monitored 61 them. Clinical outcomes and toxicities are consistent previous real-world evidence studies. Notably, beyond established poor prognostic factors-such as blastoid variant elevated lactate dehydrogenase-Bruton tyrosine-kinase...
Abstract Although genetics is a relevant risk factor in acute myeloid leukemia (AML), it can be minimally informative and/or not readily available for the early identification of patients at treatment failure. In randomized trial comparing standard vs high-dose induction (ClinicalTrials.gov #NCT00495287), we studied peripheral blast cell clearance (PBC) as rapid predictive assay chemotherapy response to determine whether correlates with achievement complete remission (CR), well postremission...
In acute myeloid leukemia (AML), CXCR4 expression has been correlated with leukocytosis and prognosis.We quantified by flow cytometry on leukemic cells in 142 AML patients.We confirm a correlation between high burden. Furthermore, we documented platelet count, dysplastic megakaryopoiesis, hepato-splenomegaly extra-hematological disease. NPM1-mutated displayed significantly higher intensity of compared to NPM1-wt cases: it is conceivable its clinical phenotype be driven expression.CXCR4...
This real-world prospective observational study across 21 Italian centers (CART-SIE) compares axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) outcomes in 485 patients with relapsed/refractory large B-cell lymphoma baseline characteristics matched by stabilized inverse propensity score weighting. Axi-cel versus tisa-cel had higher all-grade cytokine release syndrome (78.6% vs. 89.3%, P = 0.0017) neurotoxicity (9.9% 32.2%, < 0.0001) but also superior progression-free survival...
Introduction: In Italy, axicabtagene ciloleucel (axi-cel) is commercially available for the treatment of LBCL, including diffuse large B-cell lymphoma (DLBCL-NOS), high grade (HGBCL), transformed follicular (tFL), and PMBCL patients, relapsed/refractory (R/R) after at least two prior treatments. Methods: The CART-SIE an ongoing prospective retrospective study collecting data on outcome all consecutive patients treated with CAR-T cells. aim this analysis was to compare LBCL axi-cel in Italian...
Abstract Background. Paroxysmal nocturnal hemoglobinuria (PNH) is a unique disorder caused by PIG‐A gene mutation in stem cell clone. Its clinical picture can sometimes make challenging the distinction from other disorders, and especially myelodysplastic syndromes (MDS), since both diseases correlate with cytopenias morphological abnormalities of bone marrow (BM) cells. Recently, flow cytometry (FC) has been proposed to integrate morphologic assessment BM dysplasia, thus improve diagnostics...
<div>Abstract<p>This real-world prospective observational study across 21 Italian centers (<i>CART-SIE</i>) compares axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) outcomes in 485 patients with relapsed/refractory large B-cell lymphoma baseline characteristics matched by stabilized inverse propensity score weighting. Axi-cel versus tisa-cel had higher all-grade cytokine release syndrome (78.6% vs. 89.3%, <i>P</i> = 0.0017) neurotoxicity...
<p>Supplementary Figure 1 – Survival in entire population</p>
<p>Supplementary figure 3 – Outcomes according to bridging therapy</p>